不同剂量α干扰素治疗慢性丙型肝炎疗效及安全性观察

目的评价不同剂量α-2b干扰素联合利巴韦林治疗慢性丙型肝炎的临床疗效及安全性。方法将61例慢性丙型肝炎患者随机分为3组,接受48周的抗病毒治疗及24周的随访,其中两组分别接受5MU和3MU的α-2b干扰素联合利巴韦林治疗,另一组单用利巴韦林治疗。结果 5MU组、3MU组在48周治疗结束时ETVR分别为68.2%和61.9%,两组均显著高于单用利巴韦林组(5.6%)(P0.01);干扰素5MU组、3MU组随访24周结束时SVR为50.0%和42.9%,两组均显著高于单用利巴韦林组(0%,P0.01);不同剂量α-2b干扰素治疗组间肝纤维化指标变化和不良反应发生率无显著性差异(P0.05)。结论不同剂量α-2b干扰素治疗结束时均能获得较高的病毒学应答率和持续应答率,5MU组疗效优于3MU组,两组均可降低肝纤维化指标,改善肝脏组织学,且安全性相当。

Clinical efficacy of different doses of interferon-alfa in the management of patients with chronic hepatitis C

Objective To evaluate clinical efficacy and safety of different doses of interferon（IFN）alfa-2b in the management of patients with chronic hepatitis C. Methods 61 patients with chronic hepatitis C were randomly divided into three groups,who received 48 week treatment and 24 week follow up with IFN alfa-2b（5MU）＋ribavarin,IFN alfa-2b （3MU）＋ribavarin,ribavarin alone,respectively. Results After 48 week treatment,ETVR were 68.2% and 61.9% respectively in the groups with IFN alfa-2b（5MU）＋ribavarin and IFN alfa-2b（3MU）＋ribavarin,which were significantly higher than that in the group with ribavarin（5.6%,P0.01）;After 24 week follow up,SVR were 50.0% and 42.9% respectively in the groups with IFN alfa-2b（5MU）＋ribavarin and IFN alfa-2b（3MU）＋ribavarin,which were significantly higher than that in the group with ribavarin （0%,P0.01）;There was no difference between two groups with different doses of IFN alfa-2b in the change of liver fibrosis indexes and side-effects.Conclusion ETVR and SVR of different doses of IFN alfa-2b were satisfactory at the end of treatment,while the effect of 5MU group was better than the group of 3MU. Both of two groups were able to reduce liver fibrosis indexes and improve hepatic histology.